Rituximab therapy for patients with newly diagnosed, asymptomatic advanced-stage follicular grade I non-Hodgkin's lymphoma (NHL): A phase II trial in the North Central Cancer Treatment Group (NCCTG).

被引：0
|
作者：
Witzig, TE
Vukov, AM
Habermann, TM
Geyer, S
Friedenberg, WR
White, WL
Salim, M
Flynn, PJ
Fitch, TR
Morton, RF
机构：
[1] Mayo Clin, Rochester, MN USA
[2] OHACI, Peoria, IL USA
[3] Guthrie Clin, Milan, Italy
[4] Allan Blair Canc Ctr, Regina, SK, Canada
[5] Oncolog Consultants PA, Minneapolis, MN USA
[6] Mayo Clin, Scottsdale, AZ USA
[7] Iowa Oncol Res Assoc CCOP, Med Oncol & Med Assoc, Des Moines, IA USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1398
引用
收藏
页码：361A / 361A
页数：1
相关论文
共 50 条
  • [31] First-Line Radio-Immunotherapy of Newly Diagnosed, Advanced Follicular Non-Hodgkin Lymphoma with 131I-Rituximab: The INITIAL Study
    McQuillan, Andrew D.
    Macdonald, William B. G.
    Leahy, Michael F.
    Turner, J. Harvey
    BLOOD, 2011, 118 (21) : 1589 - 1589
  • [32] Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma
    Spina, Michele
    Simonelli, Cecilia
    Tirelli, Umberto
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (06) : E7 - E7
  • [33] Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study
    Evens, Andrew M.
    Smith, Mitchell R.
    Lossos, Izidore S.
    Helenowski, Irene
    Millenson, Michael
    Winter, Jane N.
    Rosen, Steve T.
    Gordon, Leo I.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (04) : 514 - 520
  • [34] Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma
    Boue, Francois
    Gabarre, Jean
    Gisselbrecht, Christian
    Reynes, Jacques
    Cheret, Antoine
    Bonnet, Fabrice
    Billaud, Eric
    Raphael, Martine
    Lancar, Remi
    Costagliola, Dominique
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (25) : 4123 - 4128
  • [35] CHOP followed by tositumomab/iodine I 131 tositumomab (BEXXAR®) for treatment of newly diagnosed follicular non-Hodgkin's lymphomas:: A phase II trial of the Southwest Oncology Group (S9911).
    Press, OW
    Unger, JM
    Braziel, RM
    Maloney, DM
    Miller, TP
    LeBlanc, M
    Fisher, RI
    BLOOD, 2003, 102 (11) : 29A - 29A
  • [36] Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate- or high-grade non-Hodgkin's lymphoma (NHL).
    Vose, JM
    Link, BK
    Grossbard, ML
    Fisher, RI
    Czuczman, M
    Grillo-Lopez, A
    Gilman, P
    Lowe, A
    Kunkel, LA
    BLOOD, 1999, 94 (10) : 89A - 89A
  • [37] Pretargeted radioimmunotherapy (PRIT™) for treatment of non-Hodgkin's lymphoma (NHL):: Initial phase I/II study results
    Weiden, PL
    Breitz, HB
    Press, O
    Appelbaum, JW
    Bryan, JK
    Gaffigan, S
    Stone, D
    Axworthy, D
    Fisher, D
    Reno, J
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2000, 15 (01) : 15 - 29
  • [38] Phase II trial of abbreviated CHOP-Rituximab followed by 90Y ibritumomab tiuxetan (Zevalin) and rituximab in patients with previously-untreated follicular non-Hodgkin lymphoma (NHL).
    DeMonaco, NA
    Wu, M
    Osborn, J
    Evans, T
    Foon, KA
    Swerdlow, SH
    Kant, J
    Joyce, J
    Land, SR
    Jacobs, SA
    BLOOD, 2005, 106 (11) : 689A - 689A
  • [39] Phase II multicenter trial of pentostatin and rituximal in patients with previously treated and untreated non-Hodgkin's lymphoma (NHL)
    Yunus, F
    George, S
    Smith, J
    Geils, G
    Geils, G
    BLOOD, 2003, 102 (11) : 642A - 643A
  • [40] A new protocol (BMMP) for the treatment of refractory or relapsed high-grade non-Hodgkin's lymphomas (NHL) of advanced stage: A phase I study
    Kahl, C
    Herold, M
    JentschUllrich, K
    Wolf, HH
    Hoffkes, HG
    Franke, A
    BLOOD, 1996, 88 (10) : 3495 - 3495
12345